Sort
40,608 grants matching “prostate cancer”
Western Regional Community Clinical Oncology Program
$407,540Banner Good Samaritan Medical Center · U10 · FY2003 · CA
Utilizing islet autoantibody signatures for precision medicine in type 2 diabetes
$407,408Nisa M Maruthur · Johns Hopkins University · R01 · FY2023 · DK
Novel chemokine in the regulation of breast cancer metastasis
$407,391Dev Karan · University Of Louisville · R21 · FY2024 · CA
Pharmacogenetic Studies
$407,387Neil E. Caporaso · Division Of Cancer Epidemiology And Genetics · ZIA · FY2017 · CA
A non-canonical role for EZH2 in rRNA methtlation
$407,287Qi Cao · Northwestern University At Chicago · R01 · FY2024 · CA
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors
$407,175Eliezer M Van Allen · Dana-Farber Cancer Inst · R01 · FY2020 · CA
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors
$407,175Eliezer M Van Allen · Dana-Farber Cancer Inst · R01 · FY2021 · CA
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors
$407,175Eliezer M Van Allen · Dana-Farber Cancer Inst · R01 · FY2022 · CA
CAREER: Microscopic (<100 um) imaging in centimeter-deep tissues based on an ultrasound-switchable fluorescence technique
$407,163Baohong Yuan · University Of Texas At Arlington · · FY2013 · ENG
Determining the role of lipid droplets in glioblastoma and their therapeutic potential
$407,145Deliang Guo · Ohio State University · R01 · FY2018 · NS
LHRH Agonist Therapy and Cognitive Functioning in Men with Prostate Cancer
$407,088Paul B Jacobsen · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2011 · CA
Phase I Clinical Trials of Novel Agents
$407,039Sloan-Kettering Institute For Cancer Res · U01 · FY2005 · CA
Signaling importance of âfunctionlessâ lyso-PAF, an inactive form of platelet activating factor, in melanoma with mutant Nras
$407,027Jing Chen · University Of Chicago · R01 · FY2022 · CA
The role of MnSOD allelic variations in prostate cancer etiology and outcome
$407,025Alan Diamond · University Of Illinois At Chicago · R01 · FY2017 · CA
Controlled Release of Macromolecules
$407,004Robert S Langer · Massachusetts Institute Of Technology · R37 · FY2008 · EB
Detection of prostate cancer using circulating tumor DNA
$406,997Adam Sowalsky · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Cancer stem cells and human liver cancer
$406,993Snorri Thorgeirsson · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Molecular Epidemiology of Prostate Cancer Outcomes: Genetics, Multilevel Environ
$406,990Timothy R Rebbeck · University Of Pennsylvania · P60 · FY2015 · MD
Epigenetic mechanisms of drug resistance in renal cell carcinoma
$406,936Roberto Pili · Indiana University Indianapolis · R01 · FY2020 · CA
Age-related shifts in epithelial lineages and tissue homeostasis in mammary gland
$406,935Mark A Labarge · University Of Calif-Lawrenc Berkeley Lab · R01 · FY2014 · AG
A First-in-Class FAP-activated Protoxin to disrupt the Tumor-Stroma Parasitic Cycle fueling lethal Prostate Cancer Progression
$406,852William Nathaniel Brennen · Johns Hopkins University · R01 · FY2023 · CA
Urban Latino African American Cancer Disparities Project
$406,816David C Khan · 21st Century Oncology Of California · U56 · FY2007 · CA
Targeting eIF4A1-dependent HK2 translation axis for prevention of castration-resistant prostate cancer
$406,786Yibin Deng · University Of Minnesota · R01 · FY2019 · CA
ALLOGENIC PANCREATIC TUMOR VACCINE CELL LINE
$406,745Johns Hopkins University · R01 · FY2001 · CA
Cell Growth Signaling in Cancer Development
$406,715David M Sabatini · Whitehead Institute For Biomedical Res · R01 · FY2009 · CA